NASDAQ:HRMY

Harmony Biosciences Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy HRMY

*Your capital is at risk

$33.43

+0.150 (+0.451%)

At Close: Jun 22, 2026

Harmony Biosciences Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 21.21. In total, the insiders bought 1.95M and sold 13.43M HRMY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	21.21
● Buy	1.95M shares
● Sell	13.43M shares
77% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence Apr 14, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 21.21. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 14, 2026 Buy	Stock Option A-Award	Graf R. Mark Director	Director	21 872 Value: $672.8K
May 14, 2026 Buy	Stock Option A-Award	Philip Ron M Director	Director	21 872 Value: $672.8K
May 14, 2026 Buy	Stock Option A-Award	Szyper Linda M Director	Director	21 872 Value: $672.8K
May 14, 2026 Buy	Stock Option A-Award	Germano Geno J Director	Director	21 231 Value: $653.1K
May 14, 2026 Buy	Common Stock J-Other	Germano Geno J Insider	Other	0 Value: $0
May 14, 2026 Buy	Stock Option A-Award	Sabater Juan A. Director	Director	21 872 Value: $672.8K
May 14, 2026 Buy	Stock Option A-Award	Sender Gary Director	Director	21 872 Value: $672.8K
May 01, 2026 Sell	Common Stock F-InKind	Budur Kumar Chief Medical Officer	Officer	8 882 Value: $282.7K
May 01, 2026 Buy	Common Stock M-Exempt	Budur Kumar Chief Medical Officer	Officer	18 750 Value: $596.8K
May 01, 2026 Buy	Restricted Stock Units M-Exempt	Budur Kumar Chief Medical Officer	Officer	18 750 Value: $596.8K
Apr 14, 2026 Buy	Stock Option A-Award	Reicin Glenn Chief Financial Officer	C-Suite Officer	164 309 Value: $4.81M
Apr 14, 2026 Buy	Common Stock J-Other	Reicin Glenn Insider	Other	0 Value: $0
Apr 07, 2026 Buy	Common Stock M-Exempt	Zaeske Adam H. Chief Commercial Officer	Officer	7 500 Value: $207.2K
Apr 07, 2026 Buy	Restricted Stock Units M-Exempt	Zaeske Adam H. Chief Commercial Officer	Officer	7 500 Value: $207.2K
Apr 07, 2026 Sell	Common Stock F-InKind	Zaeske Adam H. Chief Commercial Officer	Officer	3 173 Value: $87.6K
Apr 02, 2026 Buy	Common Stock J-Other	Ignelzi Troy A. Insider	Other	0 Value: $0
Apr 02, 2026 Buy	Stock Option A-Award	Ignelzi Troy A. Director	Director	17 710 Value: $491.3K
Apr 02, 2026 Buy	Stock Option A-Award	Anastasiou Peter Chief Operating Officer	C-Suite Officer	212 241 Value: $5.89M
Jan 26, 2026 Sell	Common Stock S-Sale	Kapadia Sandip Chief Financial Officer	C-Suite Officer	3 746 Value: $139.2K
Jan 25, 2026 Sell	Common Stock F-InKind	Budur Kumar Chief Medical Officer	Officer	1 372 Value: $50.5K
Jan 25, 2026 Buy	Common Stock M-Exempt	Budur Kumar Chief Medical Officer	Officer	2 662 Value: $89.0K
Jan 25, 2026 Buy	Restricted Stock Units M-Exempt	Budur Kumar Chief Medical Officer	Officer	2 662 Value: $89.0K
Jan 25, 2026 Buy	Restricted Stock Units M-Exempt	Kapadia Sandip Chief Financial Officer	C-Suite Officer	4 725 Value: $158.0K
Jan 25, 2026 Buy	Common Stock M-Exempt	Kapadia Sandip Chief Financial Officer	C-Suite Officer	4 725 Value: $158.0K
Jan 25, 2026 Sell	Common Stock F-InKind	Kapadia Sandip Chief Financial Officer	C-Suite Officer	2 553 Value: $94.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HARMONY BIOSCIENCES HOLDINGS, INC.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...

Read Full Profile Here